OncoMatch/Clinical Trials/NCT07236112

Study of TRDC002 in the Diagnosis of Patients With PSMA-positive Prostate Cancer

Is NCT07236112 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Intravenous (IV) single dose for prostate cancer.

Phase 1RecruitingC Ray TherapeuticsNCT07236112Data as of May 2026

Treatment: Intravenous (IV) single dose — TRDC002 uses a radioactive form (64Cu) to trace the PSMA positive prostate cancer. The purpose of this study is to investigate TRDC002 as a PSMA PET tracer to localize PSMA positive lesions in adult patients with recurrent or metastatic prostate cancer. We plan to assess the PSMA PET/CT image quality following administration of two dose levels of TRDC002 to determine an acceptable dose and optimal acquisition time for obtaining diagnostic quality PET/CT images. The safety and tolerability, PK, biodistribution, dosimetry of TRDC002 will also be evaluated in this study.

Check if I qualify

Extracted eligibility criteria

Cancer type

Prostate Cancer

Biomarker criteria

Required: FOLH1 PSMA-positive lesions

Participants with PSMA-positive lesions.

Disease stage

Metastatic disease required

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Cannot have received: immunotherapy or biological therapy targeting PSMA

Any immunotherapy or biological therapy (including antibodies) targeting PSMA within 60 days prior to the day of randomization.

Lab requirements

Blood counts

Kidney function

Liver function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify